NASDAQ:JNCE Jounce Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Jounce Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.89 -0.07 (-0.88 %) (As of 09/24/2020 12:00 AM ET) Add Compare Share Today's Range$7.24Now: $7.89▼$8.0750-Day Range$4.57MA: $6.42▼$10.9552-Week Range$2.79Now: $7.89▼$11.72Volume907,525 shsAverage Volume647,855 shsMarket Capitalization$268.80 millionP/E Ratio12.73Dividend YieldN/ABeta2.11 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform. It is also developing JTX-4014, a monoclonal antibody that is in Phase I clinical trial for combination therapy; and JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2 that is in the IND-enabling phase. The company has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.2 Analyst's Opinion Consensus RatingJounce Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 3 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.33, Jounce Therapeutics has a forecasted upside of 107.0% from its current price of $7.89.Amount of Analyst CoverageJounce Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesJounce Therapeutics has received 259 “outperform” votes. (Add your “outperform” vote.)Underperform VotesJounce Therapeutics has received 228 “underperform” votes. (Add your “underperform” vote.)Community SentimentJounce Therapeutics has received 53.18% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Jounce Therapeutics and other stocks. Vote “Outperform” if you believe JNCE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe JNCE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldJounce Therapeutics does not currently pay a dividend.Dividend GrowthJounce Therapeutics does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Jounce Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $176,378.00 in company stock.Percentage Held by Insiders43.96% of the stock of Jounce Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions74.08% of the stock of Jounce Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Jounce Therapeutics are expected to grow in the coming year, from ($2.99) to ($2.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jounce Therapeutics is 12.73, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 18.12.Price to Earnings Ratio vs. SectorThe P/E ratio of Jounce Therapeutics is 12.73, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.19.Price to Book Value per Share RatioJounce Therapeutics has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.96 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:JNCE Previous Symbol CUSIPN/A CIK1640455 Webwww.jouncetx.com Phone857-259-3840Debt Debt-to-Equity Ratio0.12 Current Ratio8.04 Quick Ratio8.04Price-To-Earnings Trailing P/E Ratio12.73 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$147.87 million Price / Sales1.82 Cash Flow$1.59 per share Price / Cash Flow4.97 Book Value$5.25 per share Price / Book1.50Profitability EPS (Most Recent Fiscal Year)$1.66 Net Income$56.82 million Net MarginsN/A Return on Equity13.49% Return on Assets11.31%Miscellaneous Employees115 Outstanding Shares34,068,000Market Cap$268.80 million Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $7.89 -0.07 (-0.88 %) (As of 09/24/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive JNCE News and Ratings via Email Sign-up to receive the latest news and ratings for JNCE and its competitors with MarketBeat's FREE daily newsletter. Jounce Therapeutics (NASDAQ:JNCE) Frequently Asked Questions How has Jounce Therapeutics' stock been impacted by COVID-19? Jounce Therapeutics' stock was trading at $4.28 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, JNCE stock has increased by 84.3% and is now trading at $7.89. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Jounce Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Jounce Therapeutics. When is Jounce Therapeutics' next earnings date? Jounce Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Jounce Therapeutics. How were Jounce Therapeutics' earnings last quarter? Jounce Therapeutics Inc (NASDAQ:JNCE) announced its quarterly earnings results on Friday, August, 7th. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.72) by $0.10. View Jounce Therapeutics' earnings history. What price target have analysts set for JNCE? 5 equities research analysts have issued 1 year target prices for Jounce Therapeutics' stock. Their forecasts range from $9.00 to $28.00. On average, they anticipate Jounce Therapeutics' stock price to reach $16.33 in the next year. This suggests a possible upside of 107.0% from the stock's current price. View analysts' price targets for Jounce Therapeutics. Who are some of Jounce Therapeutics' key competitors? Some companies that are related to Jounce Therapeutics include Compugen (CGEN), Regenxbio (RGNX), Adaptimmune Therapeutics (ADAP), I-Mab (BDTX), Translate Bio (TBIO), Atara Biotherapeutics (ATRA), Alector (ALEC), Adverum Biotechnologies (ADVM), Replimune Group (REPL), Krystal Biotech (KRYS), Vericel (VCEL), Vaxart (VXRT), Nantkwest (NK), Cellectis (CLLS) and Agenus (AGEN). View all competitors. What other stocks do shareholders of Jounce Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Jounce Therapeutics investors own include Exelixis (EXEL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Crispr Therapeutics (CRSP), Novavax (NVAX), Mylan (MYL), Progenics Pharmaceuticals (PGNX), Adaptimmune Therapeutics (ADAP), Incyte (INCY) and Nektar Therapeutics (NKTR). Who are Jounce Therapeutics' key executives? Jounce Therapeutics' management team includes the following people: Dr. Richard Murray, Pres, CEO & Director (Age 60)Mr. Hugh M. Cole, Chief Bus. Officer & Head of Corp. Devel. (Age 54)Dr. Elizabeth G. Tréhu, Chief Medical Officer (Age 59)Dr. James P. Allison, FounderDr. Thomas F. Gajewski, Founder When did Jounce Therapeutics IPO? (JNCE) raised $76 million in an initial public offering (IPO) on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers. What is Jounce Therapeutics' stock symbol? Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE." Who are Jounce Therapeutics' major shareholders? Jounce Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include AQR Capital Management LLC (1.33%), Charles Schwab Investment Management Inc. (0.83%), Russell Investments Group Ltd. (0.62%), Bank of New York Mellon Corp (0.59%), Jacobs Levy Equity Management Inc. (0.53%) and Sei Investments Co. (0.40%). Company insiders that own Jounce Therapeutics stock include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin and Richard /Ca/ Murray. View institutional ownership trends for Jounce Therapeutics. Which institutional investors are selling Jounce Therapeutics stock? JNCE stock was sold by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc., Marshall Wace LLP, AQR Capital Management LLC, Essex Investment Management Co. LLC, Strs Ohio, Prudential Financial Inc., Two Sigma Advisers LP, and Goldman Sachs Group Inc.. Company insiders that have sold Jounce Therapeutics company stock in the last year include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin, and Richard /Ca/ Murray. View insider buying and selling activity for Jounce Therapeutics. Which institutional investors are buying Jounce Therapeutics stock? JNCE stock was purchased by a variety of institutional investors in the last quarter, including Charles Schwab Investment Management Inc., Sei Investments Co., Raymond James Financial Services Advisors Inc., Principal Financial Group Inc., Principal Financial Group Inc., New York State Common Retirement Fund, Navellier & Associates Inc, and Captrust Financial Advisors. View insider buying and selling activity for Jounce Therapeutics. How do I buy shares of Jounce Therapeutics? Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Jounce Therapeutics' stock price today? One share of JNCE stock can currently be purchased for approximately $7.89. How big of a company is Jounce Therapeutics? Jounce Therapeutics has a market capitalization of $268.80 million and generates $147.87 million in revenue each year. The company earns $56.82 million in net income (profit) each year or $1.66 on an earnings per share basis. Jounce Therapeutics employs 115 workers across the globe. What is Jounce Therapeutics' official website? The official website for Jounce Therapeutics is www.jouncetx.com. How can I contact Jounce Therapeutics? Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840. This page was last updated on 9/25/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
